Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans.

Drug induced liver injury (DILI) is a major cause of attrition during early and late stage drug development. Consequently, there is a need to develop better in vitro primary hepatocyte models from different species for predicting hepatotoxicity in both animals and humans early in drug development. Dog is often chosen as the non-rodent species for toxicology studies. Unfortunately, dog in vitro models allowing long term cultures are not available. The objective of the present manuscript is to describe the development of a co-culture dog model for predicting hepatotoxic drugs in humans and to compare the predictivity of the canine model along with primary human hepatocytes and HepG2 cells. After rigorous optimization, the dog co-culture model displayed metabolic capacities that were maintained up to 2 weeks which indicates that such model could be also used for long term metabolism studies. Most of the human hepatotoxic drugs were detected with a sensitivity of approximately 80% (n=40) for the three cellular models. Nevertheless, the specificity was low approximately 40% for the HepG2 cells and hepatocytes compared to 72.7% for the canine model (n=11). Furthermore, the dog co-culture model showed a higher superiority for the classification of 5 pairs of close structural analogs with different DILI concerns in comparison to both human cellular models. Finally, the reproducibility of the canine system was also satisfactory with a coefficient of correlation of 75.2% (n=14). Overall, the present manuscript indicates that the dog co-culture model may represent a relevant tool to perform chronic hepatotoxicity and metabolism studies.

[1]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  T. Singer,et al.  A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  R. Beresford,et al.  Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. , 1986, Drugs.

[4]  S. V. van IJzendoorn,et al.  Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells. , 2006, Molecular biology of the cell.

[5]  L. Laine,et al.  A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience , 2006, Pharmacoepidemiology and drug safety.

[6]  Jiri Aubrecht,et al.  Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. , 2010, Toxicology letters.

[7]  M. Giorgi,et al.  Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs. , 2012, American journal of veterinary research.

[8]  N. Kolatkar,et al.  Commentary on ‘case series of liver failure associated with rosiglitazone and pioglitazone’ by Floyd et al. , 2009, Pharmacoepidemiology and drug safety.

[9]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[11]  Agustín Lahoz,et al.  Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  A. Brown,et al.  A history of the role of the hERG channel in cardiac risk assessment. , 2013, Journal of pharmacological and toxicological methods.

[13]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[14]  P L Morselli,et al.  Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. , 1992, Drug metabolism reviews.

[15]  D. Greenblatt,et al.  Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies , 2001, Journal of clinical pharmacology.

[16]  K. Hoffmann Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[17]  G. Labbe,et al.  Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  I. Wilson,et al.  Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Yvonne Will,et al.  Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  K. Tilmant,et al.  Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins , 2012, Cell Biology and Toxicology.

[21]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.

[22]  Yvonne Will,et al.  Evaluation of drugs with specific organ toxicities in organ-specific cell lines. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  L. Kaminsky,et al.  Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. , 1995, Biochemical pharmacology.

[24]  V. Kukes,et al.  Experimental and Clinical Pharmacokinetics of Amitryptiline: Comparative Analysis , 2009, Bulletin of Experimental Biology and Medicine.

[25]  I. Irwin,et al.  Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs , 2009, British journal of pharmacology.

[26]  Y. Seo,et al.  Base excision DNA repair defect in thioredoxin-1 (Trx1)-deficient cells. , 2013, Mutation research.

[27]  V. Nosikov,et al.  Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension , 2007, Fundamental & clinical pharmacology.

[28]  Dong Joon Kim,et al.  Drug-induced liver injury: present and future , 2012, Clinical and molecular hepatology.

[29]  T. Shimizu,et al.  Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. , 1998, Pharmacogenetics.

[30]  E. Rondinelli,et al.  CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians , 2004, Clinical pharmacology and therapeutics.

[31]  Dolores Diaz,et al.  Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. , 2004, Chemico-biological interactions.

[32]  P. Vasseur,et al.  Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[33]  A. Beiderbeck,et al.  Commentary on ‘case series of liver failure associated with rosiglitazone and pioglitazone’ by James Floyd et al , 2009, Pharmacoepidemiology and drug safety.

[34]  K. Ward,et al.  Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  P. Lurie,et al.  Case series of liver failure associated with rosiglitazone and pioglitazone , 2009, Pharmacoepidemiology and drug safety.

[36]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[37]  J. Remon,et al.  Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. , 2011, Research in veterinary science.

[38]  Albert P. Li,et al.  Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. , 2012, Chemico-biological interactions.

[39]  Helga Gerets,et al.  Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[41]  P. Vasseur,et al.  The automated micronucleus assay for early assessment of genotoxicity in drug discovery. , 2013, Mutation research.

[42]  F. Atienzar,et al.  Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[43]  O. Sugita,et al.  Drug metabolism by the human hepatoma cell, Hep G2. , 1987, Biochemical and biophysical research communications.

[44]  Y. Sugiyama,et al.  Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[45]  J. Duan,et al.  A high throughput in vitro mrp2 assay to predict in vivo biliary excretion , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[46]  T. Guentert,et al.  Acceleration of the elimination of tenoxicam by cholestyramine in the dog. , 1986, The Journal of pharmacology and experimental therapeutics.

[47]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[48]  K. Haasio Toxicology and safety of COMT inhibitors. , 2010, International review of neurobiology.

[49]  M Antonsson,et al.  Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[50]  Osamu Okazaki,et al.  Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach , 2011, Drug Metabolism and Disposition.

[51]  Melvin E Andersen,et al.  Long‐Term Stability of Primary Rat Hepatocytes in Micropatterned Cocultures , 2013, Journal of biochemical and molecular toxicology.

[52]  S. Schenker,et al.  Effect of short‐term ethanol administration on lorazepam clearance , 1981, Hepatology.

[53]  James S MacDonald,et al.  Toxicity testing in the 21st century: a view from the pharmaceutical industry. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[54]  R. Ulrich,et al.  Idiosyncratic toxicity: a convergence of risk factors. , 2007, Annual review of medicine.

[55]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[56]  Melvin E. Andersen,et al.  Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.

[57]  Meng Li,et al.  Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[58]  F. Atienzar,et al.  Evaluation of Impedance-Based Label-Free Technology as a Tool for Pharmacology and Toxicology Investigations , 2013, Biosensors.

[59]  M. Yliperttula,et al.  Peptide nanofiber hydrogel induces formation of bile canaliculi structures in three-dimensional hepatic cell culture. , 2012, Tissue engineering. Part A.

[60]  M. Yarmush,et al.  Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. , 2009, Biochemical pharmacology.

[61]  K. Maeda,et al.  Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4 , 2011, Drug Metabolism and Disposition.

[62]  T J Maguire,et al.  Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. , 2009, Current drug metabolism.

[63]  S. Feinstein,et al.  Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. , 2009, Chemistry & biology.

[64]  M. Yarmush,et al.  A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.

[65]  Etienne Hanon,et al.  The Use of Real-Time Cell Analyzer Technology in Drug Discovery: Defining Optimal Cell Culture Conditions and Assay Reproducibility with Different Adherent Cellular Models , 2011, Journal of biomolecular screening.

[66]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[67]  Masashi Yabuki,et al.  Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins , 2009, Drug Metabolism and Disposition.

[68]  J. Mckim Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance , 2010, Combinatorial chemistry & high throughput screening.

[69]  Nigel Greene,et al.  Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. , 2010, Bioorganic & medicinal chemistry letters.

[70]  R. Barkin Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms , 2007, American journal of therapeutics.

[71]  K. Olkkola,et al.  Midazolam and other benzodiazepines. , 2008, Handbook of experimental pharmacology.

[72]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.